EATON VANCE MANAGEMENT - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 270 filers reported holding BIO-TECHNE CORP in Q1 2017. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
EATON VANCE MANAGEMENT ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2022$11,165,000
-11.6%
39,312
+7.9%
0.02%
-5.6%
Q2 2022$12,634,000
-21.5%
36,447
-1.9%
0.02%
-5.3%
Q1 2022$16,090,000
+39.9%
37,157
+67.2%
0.02%
+35.7%
Q4 2021$11,501,000
+10.3%
22,229
+0.1%
0.01%0.0%
Q3 2021$10,423,000
+3.2%
22,200
-1.0%
0.01%0.0%
Q2 2021$10,102,000
+21.7%
22,435
+3.2%
0.01%
+16.7%
Q1 2021$8,299,000
-39.5%
21,730
-49.7%
0.01%
+9.1%
Q4 2020$13,714,000
+182.5%
43,186
+120.4%
0.01%
+22.2%
Q3 2020$4,854,000
-9.3%
19,593
-3.3%
0.01%
-18.2%
Q2 2020$5,352,000
+33.6%
20,269
-4.0%
0.01%
+10.0%
Q1 2020$4,006,000
-13.0%
21,124
+0.7%
0.01%
+11.1%
Q4 2019$4,606,000
+12.2%
20,9850.0%0.01%0.0%
Q3 2019$4,106,000
-6.1%
20,9850.0%0.01%
-10.0%
Q2 2019$4,375,000
+5.2%
20,985
+0.1%
0.01%0.0%
Q1 2019$4,160,000
+37.2%
20,9540.0%0.01%
+25.0%
Q4 2018$3,032,000
+145.1%
20,954
+245.7%
0.01%
+166.7%
Q3 2018$1,237,000
+38.8%
6,062
+0.7%
0.00%
+50.0%
Q2 2018$891,000
-51.0%
6,019
-50.0%
0.00%0.0%
Q1 2018$1,818,000
+452.6%
12,032
+374.6%
0.00%
+100.0%
Q4 2017$329,000
+6.1%
2,535
-1.2%
0.00%0.0%
Q3 2017$310,000
+2.6%
2,5660.0%0.00%0.0%
Q2 2017$302,000
+16.2%
2,566
+0.4%
0.00%0.0%
Q1 2017$260,000
-0.4%
2,557
+0.7%
0.00%0.0%
Q4 2016$261,000
-4.0%
2,540
+2.4%
0.00%0.0%
Q3 2016$272,000
-3.9%
2,480
-1.1%
0.00%0.0%
Q2 2016$283,0002,5080.00%
Other shareholders
BIO-TECHNE CORP shareholders Q1 2017
NameSharesValueWeighting ↓
ROWLANDMILLER & PARTNERS.ADV 47,975$3,701,7510.85%
Diversified Trust Co 13,882$1,071,1350.04%
Czech National Bank 27,698$2,137,1780.03%
FULTON BANK, N.A. 5,444$420,0580.02%
DnB Asset Management AS 27,637$2,132,4710.01%
Versant Capital Management, Inc 36$2,7780.00%
MASSMUTUAL TRUST CO FSB/ADV 371$28,6260.00%
Bartlett & Co. LLC 172$130.00%
View complete list of BIO-TECHNE CORP shareholders